Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Good Old Fashion Tree Shake

<< Previous

Bullboard Posts

Next >>

Comment by clubhouse19on Dec 17, 2020 11:27am

130 Views

Post# 32128230

RE:RE:RE:RE:RE:RE:RE:RE:Good Old Fashion Tree Shake

You've got that right and you can thank the ineptness of management for that no matter how good they are on the scientific front !

moosepenny wrote:
Short time lurker, first time poster. Have a decent position in antibe (20% of my portfolio). My concern is, if dilution and a falling stock price is a conceivable path for the company to take, wouldn't that make it an attractive stock for a short sellers? It's known antibe needs to raise money, and if they do so by issuing stock, I think we can all expect a rough ride over the next little while.

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec